TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Nimotuzumab
Drug Type Antibody
TTD ID D05BKS
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 474
Pair Name Oxidized tea polyphenol, Nimotuzumab
Partner Name Oxidized tea polyphenol
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression EGFR hsa1956
Down-regulation Phosphorylation GSK3B hsa2932
Down-regulation Phosphorylation MAPK1 hsa5594
Up-regulation Cleavage PARP1 hsa142
Down-regulation Phosphorylation STAT3 hsa6774
In Vitro Model NCI-H1781 Minimally invasive lung adenocarcinoma Homo sapiens (Human) CVCL_1494
In Vivo Model NCI-H1781 cells (5 × 106 cells per mice) were subcutaneously injected into the flank of each nu/nu mice. 3 days later, the mice were treated by intraperitoneal injection OTP-3 and nimotuzumab (three times per week) for the indicated period.
Result OTP-3 can also serve as an effective therapeutic agent in NSCLC where it can augment the effects of nimotuzumab, a valuable property for combination agents.
03. Reference
No. Title Href
1 Oxidized tea polyphenol (OTP-3) targets EGFR synergistic nimotuzumab at inhibition of non-small cell lung tumor growth. Bioorg Chem. 2022 Nov;128:106084. doi: 10.1016/j.bioorg.2022.106084. Click
It has been 26248 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP